An interventional study of Exposure intervention in virtual reality and Exercise in Obesity, Exercise and Virtual Reality, sponsored by Universite du Quebec en Outaouais. Status unknown at 1 site in Canada. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Universite du Quebec en Outaouais · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 575 studies in Obesity with a site in Canada — 102 open to participants now, 151 under way, 47 of them phase 3. Obesity · Canada.
Among the 575 studies in Obesity with a site in Canada, this one is the 309th largest by planned enrollment of the 480 interventional ones that give a count, is one of 30 that started in 2021, is one of 280 with no phase, and was the 360th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →102 of the 575 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+ · Women only
McMaster University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
575 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 63 · Phase 3 98 · Phase 4 26
First in 1997; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 74 across the 480 interventional studies, 52 across the 91 observational. Of the 362 that completed or were terminated, 49 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 575 have an industry lead sponsor. The 10 most frequent:
Universite du Quebec en Outaouais is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Universite du Quebec en Outaouais has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
46 of the studies in Obesity with a site in Canada that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 575 studies in Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the project are to: i) assess the feasibility and acceptability of the protocol and the VR exposure intervention in women with obesity, and ii) obtain an estimate of the effect of VR exposure intervention associated with an exercise training on SPA, compliance, adherence and persistence to the exercise training, as well as persistence in PA practice in the middle term to calculate the sample size for a future larger randomized controlled trial (RCT) in women with obesity.
A RCT of feasibility will be carried out. Forty-five women with obesity and a high level of SPA will be randomized into one of the following three groups: 1) Exercice and VR exposure (Ex + expo), 2) Exercise and psychological intervention control (Ex + control) or 3) waiting list (WL).
The interventions will have a physical exercise training (identical for all) and a psychology intervention (different according to the condition: VR exposure or control). The feasibility and acceptability of the protocol and the VR exposure intervention will be assessed at the end of the study. SPA, PA practice, anthropometry, internalization of weight bias, body appreciation, perceived pleasure, motivational regulation, self-efficacy, affects as well as perception effort will be evaluated with questionnaires and scales validated before and after the intervention and 6 months after the end of the intervention. Sociodemographic data, depressive symptoms, problematic eating behaviors and propensity to immersion will be assessed during the initial visit only. Adherence, adherence and persistence to the PA program will be calculated at the end of the intervention. Persistence in PA practice will be calculated using data collected immediately after the end of the intervention and 6 months after the intervention.
Several studies show that a high level of social physical anxiety (SPA) can lead to avoidance and poor adherence to physical activity (PA) programs. Although this link is known and a high level of SPA is frequently found in women with obesity, no psychological intervention specific to the treatment of SPA has been developed to date. Exposure therapy is the treatment of choice for general social anxiety. However, this format of therapy can cause great discomfort for the patient and prevents complete control of the environment by the clinician. Virtual reality (VR), commonly employed in the treatment of anxiety disorders, offers a solution to these problems by allowing exposure to human stimuli in an adaptable environment and under the control of the clinician, with a reduction in stress patient discomfort.
The objectives of the project are to: i) assess the feasibility and acceptability of the protocol and the VR exposure intervention in women with obesity, and ii) obtain an estimate of the effect of VR exposure intervention associated with an exercise training on SPA, compliance, adherence and persistence to the exercise training, as well as persistence in PA practice in the middle term to calculate the sample size for a future larger randomized controlled trial (RCT) in women with obesity.
A RCT of feasibility will be carried out. Forty-five women with obesity and a high level of SPA will be randomized into one of the following three groups: 1) Exercice and VR exposure (Ex + expo), 2) Exercise and psychological intervention control (Ex + control) or 3) waiting list (WL).
The interventions will have a physical exercise training (identical for all) and a psychology intervention (different according to the condition: VR exposure or control). The feasibility and acceptability of the protocol and the VR exposure intervention will be assessed at the end of the study. SPA, PA practice, anthropometry, internalization of weight bias, body appreciation, perceived pleasure, motivational regulation, self-efficacy, affects as well as perception effort will be evaluated with questionnaires and scales validated before and after the intervention and 6 months after the end of the intervention. Sociodemographic data, depressive symptoms, problematic eating behaviors and propensity to immersion will be assessed during the initial visit only. Adherence, adherence and persistence to the PA program will be calculated at the end of the intervention. Persistence in PA practice will be calculated using data collected immediately after the end of the intervention and 6 months after the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
Behavioral: Exposure intervention in virtual reality · Behavioral: Exercise
This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
Behavioral: Exercise · Behavioral: Placebo
This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
Feasibility of the protocol and the intervention
The feasibility of the protocol will be assessed at the end of the study using the following criteria: i) the recruitment rate (number of participants recruited per month), ii) the retention rate (number of participants who have completed all the assessments and focus group and reason for dropout), iii) percentage of missing data (number of missing data out of number of total data) and iv) acceptance of randomization. The feasibility of the intervention will be evaluated at the end of the study using the following criteria: v) the participation rate (number of eligible participants who agreed to participate in the study), vi) the participation rate adherence (number of participants who completed the 8 psychological intervention sessions), vii) the attrition rate (number of participants who abandoned the psychological intervention and reasons). The achievement of the following criteria will be considered as a success factor in terms of feasibility (14, 23): i) recruitment rate ≤ 5.6,
Time frame: At the end of the study (+ 36 weeks)
Acceptability of the protocol and the intervention
The acceptability of the protocol and the intervention will be qualitatively assessed through 5 to 7 semi-structured discussion groups by teleconference via the zoom platform. The participants will be interviewed for 75 minutes in sub-groups of 6 to 8 participants on their perception, opinion and experience regarding the intervention and the implementation of the protocol (barriers, facilitators, satisfaction, perceived benefits, recommendation and improvement). An interview guide constructed for the purpose of the study will ensure consistency of the themes explored between the different groups while guiding the group facilitation.
Time frame: At the end of the intervention (+ 12 weeks)
Social physical anxiety change (0-12 weeks)
Social physical anxiety scale (validated questionnaire)
Time frame: Before and after intervention (Baseline and after 12 weeks)
Adherence to the physical activity (PA) intervention
Adherence to the PA intervention will be calculated as a percentage from the total number of sessions performed out of the 36 prescribed sessions (frequency).
Time frame: At the end of the PA intervention (after 12 weeks)
Compliance with the PA intervention
Compliance with the PA intervention will be calculated as a percentage from the number of sessions for which the participant will have prescribed the prescription compared to all sessions. For these calculations, data from heart rate monitors worn by participants during PA sessions and diaries completed by participants and the kinesiologist will be used.
Time frame: At the end of the PA intervention (after 12 weeks)
Physical activity change (0-12 weeks)
Triaxial accelerometer (Actigraph® wGT3X-BT) worn on the hip for 7 days
Time frame: Before and after intervention (Baseline and after 12 weeks)
Persistance in the practice of PA after the intervention
Triaxial accelerometer (Actigraph® wGT3X-BT) worn on the hip for 7 days
Time frame: Immediately after the intervention and at the end of the study (after 12 weeks and 36 weeks)
Propensity to immersion
Validated questionnaire
Time frame: Before the intervention (baseline)
The feeling of presence in immersion the feeling of presence in immersion
Gatineau presence questionnaire
Time frame: after each virtual reality session (weeks 1, 2, 3, 4, 5,6 , 9 amd 12)
Cybermalaise
Simulator Sickness Questionnaire
Time frame: before and after each virtual reality session (weeks 1, 2, 3, 4, 5,6 , 9 amd 12)
Sociodemographic data
age, sex,ethnocultural group, level of education, professional status
Time frame: before the intervention (baseline)
Depressive symptoms
Center Epidémiologic Scale-Depression-French ; scale (0-3) score range (0-60) higher score = higher depressive symptoms
Time frame: before the intervention (baseline)
Food disorder
Eating Attitudes Test-26 ; scale (0-3) score range (0-78), Higher scores indicating greater risk of an eating disorder
Time frame: before the intervention (baseline)
Weight Bias Internalisation change (0-12 weeks)
Modified Weight Bias Internalisation Scale, scale (1-7), range score (11-77), higher score = higher Weight Bias Internalization)
Time frame: Before and after intervention (Baseline and after 12 weeks)
Body composition change (0-12 weeks)
bio-impedance balance (Tanita MC 780U) made by research assistant
Time frame: Before and after intervention (Baseline and after 12 weeks)
Body index mass change (0-12 weeks)
scale and measuring rod to measure the size made by research assistant
Time frame: Before and after intervention (Baseline and after 12 weeks)
Waist circumference change (0-12 weeks)
tape measure made by research assistant
Time frame: Before and after intervention (Baseline and after 12 weeks)
Body Appreciation change (0-12 weeks)
Body Appreciation Scale-2, scale (1-5) score range (1-5), higher score = higher body satisfaction
Time frame: Before and after intervention (Baseline and after 12 weeks)
Perceived pleasure in physical activity in general (0-12 weeks)
Physical Activity Enjoyment Scale, scale (1-7) score (1-7) higher score = higher enjoyment
Time frame: Before and after intervention (Baseline and after 12 weeks)
Motivation change (0-12 weeks)
Behavioural Regulation In Exercise Questionnaire, scale (0-4), Higher, positive scores indicate greater relative autonomy; lower, negative scores indicate more controlled regulation.
Time frame: Before and after intervention (Baseline and after 12 weeks)
Affects during exercise change (0-12 weeks)
Felt Arousal Scale (score 1-6) higher score = higher felt arousal + Feeling Scale (score -5,5) higher score higher pleasure
Time frame: Before and after intervention (Baseline and after 12 weeks)
Self-efficacy change (0-12 weeks)
Self efficacy scale (Bandura), scale (0-100) score range (0-100) higher score = higher self efficacy
Time frame: Before and after intervention (Baseline and after 12 weeks)
Perception effort change (0-12 weeks)
Borg scale, scale and score range (0-10), higher score = higher perception of effort
Time frame: Before and after intervention (Baseline and after 12 weeks)
Started Sep 2021 (actual). Primary completion is estimated for Mar 2023, 18 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 18 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universite du Quebec en Outaouais